US6720350B2
Expired / Lapsed
US
⏱️ 0.0 years remaining
Therapeutic inhibitor of vascular smooth muscle cells
Assignee: UAB Research Foundation
•
Filing: 2002-12-27
•
Granted: 2004-04-13
•
Expires: 2022-12-27
Abstract
Abstract Methods are provided for inhibiting stenosis or restenosis following vascular trauma in a mammalian host, comprising administering to the host a therapeutically effective dosage of a cytostatic agent and/or cytoskeletal inhibitor so as to biologically stent the traumatized vessel. Also provided is a method to inhibit or reduce vascular remodeling following vascular trauma, comprising administering an effective amount of a cytoskeletal inhibitor. Further provided are pharmaceutical compositions and kits comprising the therapeutic agents of the invention.
Inventors
- 👤 Lawrence L. Kunz
- 👤 Richard A. Klein
- 👤 John M. Reno
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 14:47
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/0012; A61K9/0019; A61K9/0024; A61K31/00; A61K31/04; A61K31/13; A61K31/131; A61K31/135; A61K31/138; A61K31/16; A61K31/165; A61K31/17; A61K31/33; A61K31/335; A61K31/337; A61K31/365; A61K31/395; A61K31/40; A61K31/4025; A61K31/403; A61K31/4035; A61K31/407; A61K31/495; A61K31/505; A61K31/519; A61K31/55; A61K31/551; A61K31/70; A61K31/7028; A61K31/7034; A61K31/704; A61K47/00; A61K47/50; A61K47/51; A61K47/68; A61K47/6801; A61K47/6803; A61K47/6807; A61K47/6809; A61K47/6811; A61K47/6817; A61K47/6831; A61K47/6835; A61K47/6843; A61K47/6849; A61K47/69; A61K47/6921; A61K47/6923; A61K47/6927; A61L; A61L31/00; A61L31/08; A61L31/14; A61L31/148; A61L31/16; A61P; A61P43/00; A61P7/00; A61P9/00; A61P9/10; A61L2300/00; A61L2300/40; A61L2300/416; A61L2300/432; A61L2300/60; A61L2300/602; A61L2300/606; A61L2300/62; A61L2300/622; G; G01; G01N; G01N2800/00; G01N2800/32; G01N2800/323; Y; Y10; Y10S; Y10S977/00; Y10S977/902; Y10S977/904; Y10S977/906; Y10S977/915; Y10S977/92
Claims Analysis
Total Claims: 44
Claim 1
Independent Claim
47 words
A method for inhibiting or reducing diminution in vessel lumen area of a mammalian blood vessel comprising introducing to the vessel a therapeutic shunt comprising an amount of a cytoskeletal inhibitor effective to inhibit or reduce stenosis or restenosis of the vessel following placement of the shunt.
Claim 2
Independent Claim
47 words
A method for inhibiting or reducing diminution in vessel lumen area of a mammalian blood vessel comprising introducing to the vessel a therapeutic shunt comprising an amount of a cytoskeletal inhibitor effective to inhibit or reduce stenosis or restenosis of the vessel following placement of the shunt.
Claim 3
Dependent Claim
17 words
The method of claim 1 wherein the cytoskeletal inhibitor comprises taxol, a cytochalasin, or an analog thereof.
Claim 4
Dependent Claim
11 words
The method of claim 1 wherein the cytoskeletal inhibitor comprises taxol.
Claim 5
Dependent Claim
14 words
The method of claim 1 wherein the cytoskeletal inhibitor comprises an analog of taxol.
Claim 6
Dependent Claim
14 words
The method of claim 1 wherein the amount inhibits vascular smooth muscle cell proliferation.
Claim 7
Dependent Claim
23 words
The method of claim 1 wherein the cytoskeletal inhibitor is releasably embedded in, coated on, or embedded in and coated on, the shunt.
Claim 8
Dependent Claim
24 words
The method of claim 1 wherein the cytoskeletal inhibitor is releasably embedded in, coated on, or embedded in and coated on, a non-liquid matrix.
Claim 9
Dependent Claim
15 words
The method of claim 7 wherein the matrix is a gel, paste or permeable membrane.
Claim 10
Dependent Claim
14 words
The method of claim 1 wherein the cytoskeletal inhibitor is coated on the shunt.
Claim 11
Dependent Claim
20 words
The method of claim 1 wherein the cytoskeletal inhibitor is releasably embedded in microparticles or nanoparticles, or a mixture thereof.
Claim 12
Dependent Claim
14 words
The method of claim 1 wherein the cytoskeletal inhibitor is in substantially crystalline form.
Claim 13
Independent Claim
54 words
A method for inhibiting or reducing diminution in vessel lumen area of a mammalian blood vessel comprising introducing to the vessel a stent overlayed with an artificial graft which artificial graft comprises an amount of a cytoskeletal inhibitor effective to inhibit or reduce stenosis or restenosis of the vessel following placement of the stent.
Claim 14
Independent Claim
54 words
A method for inhibiting or reducing diminution in vessel lumen area of a mammalian blood vessel comprising introducing to the vessel a stent overlayed with an artificial graft which artificial graft comprises an amount of a cytoskeletal inhibitor effective to inhibit or reduce stenosis or restenosis of the vessel following placement of the stent.
Claim 15
Dependent Claim
17 words
The method of claim 12 wherein the cytoskeletal inhibitor comprises taxol, a cytochalasin, or an analog thereof.
Claim 16
Dependent Claim
11 words
The method of claim 12 wherein the cytoskeletal inhibitor comprises taxol.
Claim 17
Dependent Claim
14 words
The method of claim 12 wherein the cytoskeletal inhibitor comprises an analog of taxol.
Claim 18
Dependent Claim
14 words
The method of claim 12 wherein the amount inhibits vascular smooth muscle cell proliferation.
Claim 19
Dependent Claim
23 words
The method of claim 12 wherein the cytoskeletal inhibitor is releasably embedded in, coated on, or embedded in and coated on, the graft.
Claim 20
Dependent Claim
24 words
The method of claim 12 wherein the cytoskeletal inhibitor is releasably embedded in, coated on, or embedded in and coated on, a non-liquid matrix.
Claim 21
Dependent Claim
15 words
The method of claim 18 wherein the matrix is a gel, paste or permeable membrane.
Claim 22
Dependent Claim
14 words
The method of claim 12 wherein the cytoskeletal inhibitor is coated on the graft.
Claim 23
Dependent Claim
20 words
The method of claim 12 wherein the cytoskeletal inhibitor is releasably embedded in microparticles or nanoparticles, or a mixture thereof.
Claim 24
Dependent Claim
14 words
The method of claim 12 wherein the cytoskeletal inhibitor is in substantially crystalline form.
Claim 25
Independent Claim
48 words
A method for inhibiting or reducing diminution in vessel lumen area of a mammalian blood vessel comprising introducing to the vessel a therapeutic adventitial wrap comprising an amount of a cytoskeletal inhibitor effective to inhibit or reduce stenosis or restenosis of the vessel following placement of the wrap.
Claim 26
Independent Claim
48 words
A method for inhibiting or reducing diminution in vessel lumen area of a mammalian blood vessel comprising introducing to the vessel a therapeutic adventitial wrap comprising an amount of a cytoskeletal inhibitor effective to inhibit or reduce stenosis or restenosis of the vessel following placement of the wrap.
Claim 27
Dependent Claim
17 words
The method of claim 23 wherein the cytoskeletal inhibitor comprises taxol, a cytochalasin, or an analog thereof.
Claim 28
Dependent Claim
11 words
The method of claim 23 wherein the cytoskeletal inhibitor comprises taxol.
Claim 29
Dependent Claim
14 words
The method of claim 23 wherein the cytoskeletal inhibitor comprises an analog of taxol.
Claim 30
Dependent Claim
14 words
The method of claim 23 wherein the amount inhibits vascular smooth muscle cell proliferation.
Claim 31
Dependent Claim
23 words
The method of claim 23 wherein the cytoskeletal inhibitor is releasably embedded in, coated on, or embedded in and coated on, the wrap.
Claim 32
Dependent Claim
24 words
The method of claim 23 wherein the cytoskeletal inhibitor is releasably embedded in, coated on, or embedded in and coated on, a non-liquid matrix.
Claim 33
Dependent Claim
15 words
The method of claim 29 wherein the matrix is a gel, paste or permeable membrane.
Claim 34
Dependent Claim
20 words
The method of claim 23 wherein the cytoskeletal inhibitor is releasably embedded in microparticles or nanoparticles, or a mixture thereof.
Claim 35
Dependent Claim
14 words
The method of claim 23 wherein the cytoskeletal inhibitor is in substantially crystalline form.
Claim 36
Independent Claim
47 words
A method for inhibiting or reducing diminution in vessel lumen area of a mammalian blood vessel comprising introducing to the vessel a therapeutic artificial graft comprising an amount of a cytochalasin effective to inhibit or reduce stenosis or restenosis of the vessel following placement of the graft.
Claim 37
Independent Claim
47 words
A method for inhibiting or reducing diminution in vessel lumen area of a mammalian blood vessel comprising introducing to the vessel a therapeutic artificial graft comprising an amount of a cytochalasin effective to inhibit or reduce stenosis or restenosis of the vessel following placement of the graft.
Claim 38
Dependent Claim
11 words
The method of claim 33 wherein the cytochalasin comprises cytochalasin A.
Claim 39
Dependent Claim
11 words
The method of claim 33 wherein the cytochalasin comprises cytochalasin B.
Claim 40
Dependent Claim
14 words
The method of claim 33 wherein the cytochalasin comprises an analog of cytochalasin B.
Claim 41
Dependent Claim
11 words
The method of claim 33 wherein the cytochalasin comprises cytochalasin D.
Claim 42
Dependent Claim
22 words
The method of claim 33 wherein the cytochalasin is releasably embedded in, coated on, or embedded in and coated on, the graft.
Claim 43
Dependent Claim
23 words
The method of claim 33 wherein the cytochalasin is releasably embedded in, coated on, or embedded in and coated on, a non-liquid matrix.
Claim 44
Dependent Claim
13 words
The method of claim 33 wherein the cytochalasin is in substantially crystalline form.
References Cited (Backward Citations)
US4070484A
Cited
US3940422A
Cited
USRE32944E
Cited
US4093709A
Cited
US4235988A
Cited
US4732763A
Cited
US5324736A
Cited
US5098903A
Cited
US4442119A
Cited
US4389330A
Cited
US5332584A
Cited
US4675189A
Cited
US5047431A
Cited
US4485096A
Cited
US5015666A
Cited
US4879315A
Cited
US5114847A
Cited
US4485097A
Cited
US4577636A
Cited
US4512762A
Cited
US4555402A
Cited
US4664097A
Cited
US4840939A
Cited
US4867973A
Cited
US5226430A
Cited
US4897255A
Cited
US4605644A
Cited
US5284763A
Cited
US4824436A
Cited
US4826672A
Cited
US4744981A
Cited
US4906452A
Cited
US5316766A
Cited
US4935415A
Cited
US4859585A
Cited
US4962091A
Cited
US4879225A
Cited
US5416205A
Cited
US5314679A
Cited
US4839155A
Cited
EP0260066B1
Cited
US5120535A
Cited
US4994384A
Cited
US4959355A
Cited
US4968350A
Cited
US5114719A
Cited
US5093330A
Cited
EP0297946A3
Cited
US5527337A
Cited
US4835002A
Cited
US5216024A
Cited
US5221620A
Cited
US4929602A
Cited
US4997652A
Cited
US5030637A
Cited
US4973601A
Cited
US5232444A
Cited
US5468746A
Cited
US5167960A
Cited
US5213580A
Cited
US5208019A
Cited
US5066789A
Cited
EP0365863B1
Cited
US5340925A
Cited
US5268358A
Cited
EP0374044B1
Cited
US5304541A
Cited
US5032679A
Cited
US5380716A
Cited
EP0451202B1
Cited
US5015578A
Cited
US5073633A
Cited
US5356713A
Cited
US5364632A
Cited
US5026537A
Cited
US5288735A
Cited
US5407609A
Cited
US4994033A
Cited
US5268455A
Cited
US5248764A
Cited
US5395610A
Cited
US5208238A
Cited
US5346897A
Cited
US5364843A
Cited
US5242397A
Cited
US5112305A
Cited
US5043335A
Cited
EP0411893A3
Cited
US4990538A
Cited
US5009659A
Cited
US5059166A
Cited
US5176617A
Cited
US5232911A
Cited
US5049132A
Cited
US5199939B1
Cited
US5199939A
Cited
US5328471A
Cited
US5260224A
Cited
US5290271A
Cited
US5166143A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2007-04-13 | 2007-10-13 | 2008-04-13 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2011-04-13 | 2011-10-13 | 2012-04-13 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2015-04-13 | 2015-10-13 | 2016-04-13 | $7700.00 | Window Closed / Lapsed |